Abstract 391P
Background
Lip cancer represents 1-2% of malgnancies and accounts for 23.6-30% of all oral cancers. It is more common in the lower lip, However, it may appear in the upper lip also. Squamous cell carcinoma is the most common subtype. There is limited data to evaluate racial disparites into different age groups. So this study aims to evaluate the long-term survival outcome for lip cancer in the young and adults compared to the elderly and consider racial disparities.
Methods
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data of patients diagnosed with lip cancer from 2000-2020. The age groups have been classified into two groups according to the National Institute of Age and divided into young and adults if less than 65 years while the old age starting from 65 years.
Results
The majority were Caucasians (99279 patients) and 114 only were African Americans. The 5-year relative survival for lip cancer in the young and adults age group was 92.6%, while in the old age group was 88.9%; P>0.0001. The 5-year relative survival of African Americans in the young and adult age was 85.9% while for Caucasiasns it was 92.5%, and in African Americans elderly the 5-year relative survival was 60.4% while in Caucasian was 88.9%; P >0.0001. The 5-year relative survival for lip cancer in localized SEER stage at the young and adults age group was 95.4%, while in the old age group 92.4% And the 5-year relative survival for lip cancer in distant stage of the disease at young and adults age group was 52.1%, while in the old age group it was 27.7%. Patients treated with combined chemoradiotherapy had a 5-year relative survival of 52.3%, while those who had no systemic therapy had a 5-year relative survival of 93.2%.
Conclusions
In this study, the results highlight significant differences in the long-term survival outcomes; Caucasians are more susceptible to devolop lip cancer than African Americans. However, African Americans have lower survival rates than Caucasians. Due to the early discovery of lip cancer, the standard treatment modality is surgical resection, which explains the significantly decreased survival related to adjuvant chemo(radio)therapy. So we recommend to avoid the systemic therapy for less unfavrouble side effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract